Example logo GIS 26

Global Innovation Summit 2026

6 May 2026 | Basel, Switzerland

Home
Register
Register
Register

Do Youn Chun

Chief Technical Officer

AT-31 BIO Inc.

Daegu, South Korea

Leading the paradigm shift in immunology. AT-31 BIO delivers breakthrough solutions for complex immune disorders through advanced next-generation immunosuppressive therapies.

My organisation

AT-31 BIO Inc.

AT-31 BIO Inc.

other

Daegu, South Korea

AT-31 BIO Inc. aims to discover new drug candidates and develop innovative drugs that contribute to a healthy, happy society by overcoming diseases caused by dysfunctional immune systems. Currently, we are conducting empirical studies using cutting-edge research techniques on the immunosuppressive efficacy. We are also conducting preclinical studies using animal disease models to explore and establish indications for our potential drug candidates. Through these research approaches, we hope to open new horizons in the prevention and treatment of autoimmune diseases, transplant rejection, and hypersensitivity immune diseases, which represent unmet medical needs.
Read more

About me

I am a Molecular Immuno-Cell Biologist with experience developing cancer cell vaccines at the Johns Hopkins University Oncology Center. Currently, at AT-31 BIO Inc., I focus on developing treatments for autoimmune diseases, including Sjögren’s syndrome, dry eye, inflammatory bowel disease, and atopic dermatitis. I have published 95 papers and hold 28 patents.

Education and Career

Ph. D in Microbiology, Kyungpook National Uni

Johns Hopkins University, USA (Postdoctoral fellowship)

Former R&D head at Astrogen Inc., South Korea

Co-development Scientific Committee at Kyungpook Uni Hospital

Social media

Marketplace (1)